In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onset CE marks heart valve delivery catheter

This article was originally published in Clinica

Executive Summary

Onset Medical has CE marked its SoloPath endovascular access catheter for sale in Europe. The catheter is designed to deliver devices such as heart valves via the femoral and iliac arteries into the larger aortic artery. Up to 20% of patients who require replacement aortic heart valves have severe atherosclerosis in their leg arteries, the Irvine, California firm claims, which may prevent the use of newer percutaneous aortic valves being marketed in Europe by Edwards Lifesciences and Medtronic. In these patients, the valve has to be delivered either through a minimally-invasive incision near the heart or via a totally open-heart surgical procedure. The SoloPath could provide access to these diseased arteries, allowing more patients to be treated with percutaneously implanted aortic heart valves. The SoloPath can also deliver stent grafts for the treatment of aortic aneurysms. Onset expects to launch the SoloPath during the fourth quarter.

You may also be interested in...



Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.

Topics

UsernamePublicRestriction

Register

MT043942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel